Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

By LabMedica International staff writers
Posted on 07 May 2025

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including challenging-to-diagnose liver and oral cancers. More...

These innovative models have the potential to transform cancer detection in primary care, making it easier for patients to receive treatment at much earlier stages.

Currently, the UK's NHS uses prediction tools like the QCancer scores, which integrate various patient data to identify individuals at high risk for undiagnosed cancer, allowing general practitioners and specialists to refer them for further testing. Researchers from Queen Mary University of London (London, UK) and the University of Oxford (Oxford, UK) utilized anonymized electronic health records from over 7.4 million adults in England to develop two new algorithms. These models are more sensitive than existing tools and could lead to improved clinical decision-making and earlier cancer detection. Significantly, the new algorithms incorporate not only patient details like age, family history, medical diagnoses, symptoms, and general health, but also include the results of seven routine blood tests. These blood tests, which measure full blood count and liver function, serve as biomarkers to enhance early cancer diagnosis.

When compared with the current QCancer models, the new algorithms identified four additional medical conditions associated with an elevated risk of 15 different types of cancer, including those affecting the liver, kidneys, and pancreas. The new models also discovered two additional links between family history and lung or blood cancer, along with seven new symptoms—such as itching, bruising, back pain, hoarseness, flatulence, abdominal mass, and dark urine—that were associated with various types of cancer. The findings, published in Nature Communications, show that these new algorithms significantly improve diagnostic capabilities and are currently the only models applicable in primary care settings to assess the likelihood of undiagnosed liver cancer.

“These algorithms are designed to be embedded into clinical systems and used during routine GP consultations,” said Professor Julia Hippisley-Cox, Professor of Clinical Epidemiology and Predictive Medicine at Queen Mary University of London, and lead author of the study. “They offer a substantial improvement over current models, with higher accuracy in identifying cancers — especially at early, more treatable stages. They use existing blood test results which are already in the patients’ records making this an affordable and efficient approach to help the NHS meet its targets to improve its record on diagnosing cancer early by 2028.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.